These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas. Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544 [TBL] [Abstract][Full Text] [Related]
23. Management of locally advanced adenocarcinoma of the pancreas. Ryan DP; Willett CG Hematol Oncol Clin North Am; 2002 Feb; 16(1):95-103. PubMed ID: 12063831 [TBL] [Abstract][Full Text] [Related]
24. [Combination therapy in oncology (multimodal treatment) in pancreatic tumors]. Ihse I; Andersson R; Axelson J; Hansson L Chirurg; 1998 Apr; 69(4):366-70. PubMed ID: 9612618 [TBL] [Abstract][Full Text] [Related]
25. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835 [TBL] [Abstract][Full Text] [Related]
26. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344 [TBL] [Abstract][Full Text] [Related]
27. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. Cho M; Wang-Gillam A; Myerson R; Gao F; Strasberg S; Picus J; Sorscher S; Fournier C; Nagaraj G; Parikh P; Suresh R; Linehan D; Tan BR HPB (Oxford); 2015 Jul; 17(7):587-93. PubMed ID: 25800066 [TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776 [TBL] [Abstract][Full Text] [Related]
30. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Abrams RA; Winter KA; Regine WF; Safran H; Hoffman JP; Lustig R; Konski AA; Benson AB; Macdonald JS; Rich TA; Willett CG Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):809-16. PubMed ID: 21277694 [TBL] [Abstract][Full Text] [Related]
31. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749 [TBL] [Abstract][Full Text] [Related]
32. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496 [TBL] [Abstract][Full Text] [Related]
33. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. Walston S; Salloum J; Grieco C; Wuthrick E; Diaz DA; Barney C; Manilchuk A; Schmidt C; Dillhoff M; Pawlik TM; Williams TM Am J Clin Oncol; 2018 Dec; 41(12):1185-1192. PubMed ID: 29727311 [TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter? Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638 [TBL] [Abstract][Full Text] [Related]
36. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts. Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495 [TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas]. André T; Balosso J J Chir (Paris); 1999 Dec; 136(6):309-17. PubMed ID: 10675820 [TBL] [Abstract][Full Text] [Related]
38. Resection and radiochemotherapy of pancreatic cancer--the future? Link KH; Formentini A; Leder G; Fortnagel G; Sartori N; Schatz M; Beger HG Langenbecks Arch Surg; 1998 Apr; 383(2):134-44. PubMed ID: 9641886 [TBL] [Abstract][Full Text] [Related]
39. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S; Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735 [TBL] [Abstract][Full Text] [Related]
40. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Ahn DH; Williams TM; Goldstein DA; El-Rayes B; Bekaii-Saab T Cancer Treat Rev; 2016 Jan; 42():10-7. PubMed ID: 26620819 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]